Blueprint Medicines CorporationBlueprint Medicines CorporationBlueprint Medicines Corporation

Blueprint Medicines Corporation

No trades
See on Supercharts
Market capitalization
‪5.41 B‬USD
−8.37USD
‪−506.98 M‬USD
‪249.38 M‬USD
‪59.80 M‬
Beta (1Y)
1.00

About Blueprint Medicines Corporation

CEO
Kathryn Haviland
Headquarters
Cambridge
Employees (FY)
655
Founded
2008
ISIN
US09627Y1091
FIGI
BBG001MC8YF7
Blueprint Medicines Corp. is a precision therapy company, which engages in the invention of medicines for people with cancer and blood disorders. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of BPMC is 88.90 USD — it has increased by 0.59% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Blueprint Medicines Corporation stocks are traded under the ticker BPMC.
Blueprint Medicines Corporation is going to release the next earnings report on May 1, 2024. Keep track of upcoming events with our Earnings Calendar.
BPMC stock is 6.01% volatile and has beta coefficient of 1.00. Check out the list of the most volatile stocks — is Blueprint Medicines Corporation there?
One year price forecast for Blueprint Medicines Corporation has a max estimate of 125.00 USD and a min estimate of 50.00 USD.
BPMC earnings for the last quarter are −2.20 USD whereas the estimation was −2.37 USD which accounts for 7.07% surprise. Estimated earnings for the next quarter are −2.04 USD. See more details about Blueprint Medicines Corporation earnings.
Blueprint Medicines Corporation revenue for the last quarter amounts to ‪56.60 M‬ USD despite the estimated figure of ‪50.66 M‬ USD. In the next quarter revenue is expected to reach ‪67.12 M‬ USD.
Yes, you can track Blueprint Medicines Corporation financials in yearly and quarterly reports right on TradingView.
BPMC stock has fallen by 2.81% compared to the previous week, the month change is a 3.28% rise, over the last year Blueprint Medicines Corporation has showed a 83.03% increase.
BPMC net income for the last quarter is ‪−110.92 M‬ USD, while the quarter before that showed ‪−133.71 M‬ USD of net income which accounts for 17.05% change. Track more Blueprint Medicines Corporation financial stats to get the full picture.
Today Blueprint Medicines Corporation has the market capitalization of ‪5.41 B‬, it has decreased by 0.02% over the last week.
No, BPMC doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, BPMC shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Blueprint Medicines Corporation stock right from TradingView charts — choose your broker and connect to your account.
BPMC reached its all-time high on Dec 24, 2020 with the price of 125.61 USD, and its all-time low was 13.04 USD and was reached on Feb 8, 2016.
See other stocks reaching their highest and lowest prices.
As of Apr 19, 2024, the company has 655.00 employees. See our rating of the largest employees — is Blueprint Medicines Corporation on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Blueprint Medicines Corporation technincal analysis shows the neutral today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Blueprint Medicines Corporation stock shows the buy signal. See more of Blueprint Medicines Corporation technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Blueprint Medicines Corporation future price: according to them, BPMC price has a max estimate of 125.00 USD and a min estimate of 50.00 USD. Read a more detailed Blueprint Medicines Corporation forecast: see what analysts think of Blueprint Medicines Corporation and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Blueprint Medicines Corporation EBITDA is ‪−467.85 M‬ USD, and current EBITDA margin is −190.32%. See more stats in Blueprint Medicines Corporation financial statements.